Tokai Pharmaceuticals Inc Stock Nasdaq
Stocks
US88907J1079
Biotechnology & Medical Research
| Market Cap | 221M 194M 183M 167M 312M 21.19B 314M 2.19B 850M 10.81B 831M 813M 35.03B | P/E 2026 * |
-2.86x | P/E 2027 * | -3.28x |
|---|---|---|---|---|---|
| Enterprise Value | 221M 194M 183M 167M 312M 21.19B 314M 2.19B 850M 10.81B 831M 813M 35.03B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
99.67% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Tokai Pharmaceuticals Inc
| 1 day | -3.92% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 2020-09-08 | |
Paul Little
DFI | Director of Finance/CFO | 62 | 2021-03-14 |
Steven Perrin
PSD | President | 61 | 2020-09-13 |
| Director | Title | Age | Since |
|---|---|---|---|
Keith Katkin
CHM | Chairman | 54 | 2017-04-30 |
John McBride
BRD | Director/Board Member | 74 | 2017-04-30 |
| Director/Board Member | 53 | 2020-09-08 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.92% | +26.59% | - | - | 235M | |
| +0.06% | +6.49% | +60.29% | +111.13% | 74.27B | |
| -2.29% | -1.51% | +33.30% | +75.07% | 61.21B | |
| -2.05% | -3.46% | -18.60% | +352.20% | 26.38B | |
| -2.39% | +2.74% | +0.19% | -5.91% | 25.34B | |
| +0.57% | +3.66% | +25.59% | -9.37% | 20.84B | |
| +1.29% | -2.49% | +152.11% | +333.06% | 15.17B | |
| -2.44% | -0.09% | +42.50% | +164.11% | 14.41B | |
| -3.91% | -4.91% | -14.10% | +779.68% | 13.66B | |
| -1.12% | -3.04% | +15.72% | +234.56% | 11.99B | |
| Average | -1.62% | +0.03% | +33.00% | +226.06% | 29.25B | |
| Weighted average by Cap. | -1.22% | +1.01% | +36.01% | +162.09% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -111M -97.45M -91.6M -83.75M -156M -10.64B -158M -1.1B -427M -5.42B -417M -408M -17.58B | -112M -98.16M -92.27M -84.36M -158M -10.71B -159M -1.11B -430M -5.46B -420M -411M -17.71B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
